Competitive Pipeline
Globally competitive Pipeline Globally competitive Pipeline

We have a promising and diverse pipeline consisting of preclinical, early, mid and late stage products, that focus on cancer treatment for unmet medical need and significant commercial opportunities. Through our active partnership programs and original discovery efforts, we are advancing a broad range of development targets with multiple opportunities for success in different types of cancer.


Our late-stage clinical development efforts are being driven by our experienced team in our U.S. headquarters in New Jersey. We currently have three ongoing clinical programs: 

  • An FDA Fast Track-designated treatment for head and neck squamous cell carcinoma (HNSCC) 

  • A unique, phase-3 ready intravenously-administered oncolytic virus 

  • The most advanced potential first-in-class oral EP4 antagonist in clinical trials


Additionally, our scientists are actively engaged in discovery with pre-clinical assets currently in our pipeline. With our extensive investigational capabilities, we have the flexibility to quickly and aggressively pursue promising avenues of development as they emerge.


Pre-clinical
Phase Ia
Phase Ib
Phase II
Phase III
NDA
AN2025
(Buparlisib)
pan-PI3K
HNSCC
Global
PIK3CA
mutation
Global
AN0025
EP4
Multiple solid
tumors
(+Keytruda)
Global (Excluding Japan, South Korea, and partial Southeast Asia Counties)
Neo-adjuvant
rectum cancer
(+RT/CRT)
Global (Excluding Japan, South Korea, and partial Southeast Asia Counties)
AN1004
(Pelareorep)
HR+/HER2-mbc
(+Paclitaxel)
Great China Region, Singapore, South Korea
AN4005
PD-L1
Solid tumors
Global
AN6025
HPK1
Solid tumors
Global
AN3025
TNFR2
Solid tumors
Global